Jill M. Broadfoot
2012 - Vical
In 2012, Jill M. Broadfoot earned a total compensation of $839.6K as Senior Vice President, Chief Financial Officer and Secretary at Vical, a 8% increase compared to previous year.
Compensation breakdown
| Bonus | $130,000 |
|---|---|
| Option Awards | $293,493 |
| Salary | $313,120 |
| Stock Awards | $98,820 |
| Other | $4,129 |
| Total | $839,562 |
Broadfoot received $313.1K in salary, accounting for 37% of the total pay in 2012.
Broadfoot also received $130K in bonus, $293.5K in option awards, $98.8K in stock awards and $4.1K in other compensation.
Rankings
In 2012, Jill M. Broadfoot's compensation ranked 6,823rd out of 11,487 executives tracked by ExecPay. In other words, Broadfoot earned more than 40.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,823 out of 11,487 | 41st |
Division Manufacturing | 2,443 out of 4,253 | 43rd |
Major group Chemicals And Allied Products | 620 out of 1,198 | 48th |
Industry group Drugs | 424 out of 920 | 54th |
Industry Biological Products, Except Diagnostic Substances | 70 out of 160 | 56th |
Source: SEC filing on April 10, 2013.
Broadfoot's colleagues
We found two more compensation records of executives who worked with Jill M. Broadfoot at Vical in 2012.
News
aTYR PHARMA CEO Sanjay Shukla's 2023 pay falls 46% to $1.3M
April 5, 2024
aTYR PHARMA CEO Sanjay Shukla's 2021 pay jumps 75% to $1.9M
March 22, 2022
aTYR PHARMA CEO Sanjay Shukla's 2020 pay jumps 63% to $1.1M
March 23, 2021
aTYR PHARMA CEO Sanjay Shukla's 2019 pay falls 52% to $664K
April 2, 2020
aTYR PHARMA CEO Sanjay Shukla's 2018 pay falls 36% to $1.4M
March 28, 2019